Simcere and Bristol-Myers Squibb Partner on Cardiovascular Drug

Simcere Pharma has signed a second drug development deal with Bristol-Myers Squibb. Simcere will complete early development work on a potential cardiovascular drug at its own expense, and in return, Simcere will gain China rights to the molecule. BMS-795311 represents the second partnership for the two companies. More details.... Stock Symbols: (NYSE: SCR) (NYSE: BMY) Share this with colleagues:   var switchTo5x=true; stLight.options({publisher:'d7871f5b-67bc-4d30-b66f-1465d0b97213'});